Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
12:00am, Thursday, 07'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
NASDAQ Jumps Over 1% as Tech Sparks Late Rally
12:00am, Tuesday, 05'th May 2020
Stocks Analysis by Zacks Investment Research covering: Microsoft Corporation, SPDR S&P 500, Apple Inc, Amazon.com Inc. Read Zacks Investment Research's latest article on Investing.com
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Oppenheimer Believes Seattle Genetics (SGEN) Still Has Room to Grow
02:50am, Friday, 01'st May 2020
Oppenheimer analyst Silvan Tuerkcan maintained a Buy rating on Seattle Genetics (SGEN) yesterday and set a price target of $146.00. The company's shares
Oppenheimer Believes Seattle Genetics (NASDAQ: SGEN) Still Has Room to Grow
02:50am, Friday, 01'st May 2020
Oppenheimer analyst Silvan Tuerkcan maintained a Buy rating on Seattle Genetics (SGEN – Research Report) yesterday and set a price
Intellia Therapeutics Taps Semma’s Lebwohl as Chief Medical Officer
08:58pm, Thursday, 30'th Apr 2020
Intellia Therapeutics (NASDAQ: ]) has appointed David Lebwohl to serve as executive vice president and chief medical officer. He is joining the Cambridge,
Will Intellia Therapeutics, Inc. (NTLA) Report Negative Q1 Earnings? What You Should Know
04:34pm, Thursday, 30'th Apr 2020
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Intellia Therapeutics, Inc. (NTLA) Report Negative Q1 Earnings? What You Should Know
04:34pm, Thursday, 30'th Apr 2020
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia Therapeutics appoints David Lebwohl as CMO NTLA
12:06pm, Thursday, 30'th Apr 2020
Intellia Therapeutics appoints David Lebwohl as CMO NTLA
Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer
11:50am, Thursday, 30'th Apr 2020
Intellia Therapeutics, Inc. (NTLA) has named David Lebwohl, M.D., as its new executive vice president and chief medical officer. Dr. Lebwohl brings decades of biopharmaceutial leadership and drug dev
Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer
11:50am, Thursday, 30'th Apr 2020
CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) has named David Lebwohl, M.D., as its new executive vice...
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates
11:30am, Thursday, 30'th Apr 2020
CAMBRIDGE, Mass., April 30, 2020 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
Intellia Therapeutics (NASDAQ:NTLA) Downgraded by Zacks Investment Research to "Hold"
10:54am, Thursday, 30'th Apr 2020
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday, Zacks.com reports. According to Za
Crispr Therapeutics AG (CRSP) Received its Third Buy in a Row
10:36pm, Wednesday, 29'th Apr 2020
After Canaccord Genuity and Piper Sandler gave Crispr Therapeutics AG (NASDAQ: CRSP) a Buy rating last month, the company received another Buy, this time
Crispr Therapeutics AG (CRSP) Received its Third Buy in a Row
10:36pm, Wednesday, 29'th Apr 2020
After Canaccord Genuity and Piper Sandler gave Crispr Therapeutics AG (NASDAQ: CRSP) a Buy rating last month, the company received
